
This study examined the factors that influence B-cell repopulation in patients receiving rituximab, an anti-CD20 monoclonal antibody used in autoimmune diseases. The retrospective observational study analyzed data from 839 subjects who received 2,017 courses of rituximab. The study found that patient-specific factors such as age over 60, impaired kidney function, specific underlying diseases, and solid organ transplantation were associated with delayed B-cell repopulation. Additionally, co-immunosuppression with corticosteroids or azathioprine also prolonged B-cell recovery. The study suggests that adjusting rituximab dosing intervals may be beneficial for older patients or those with impaired kidney function, while caution is needed when using co-medications due to their impact on B-cell recovery.
Like
Save
Share